With the introduction of the newer nonsteroidal anti-inflammatory d r ugs (NSAIDs) and penicillamine, our therapeutic armamentarium for the rheumatoid disease group had been significantly broadened. ln addition, there has been a renewed interest in anti-malarials, the use of some immunosuppressive agents, and plasmapheresis. The purpose of this article is to offer a helpful therapeutic scheme in the selection of these newer anti-rheumatoid agents. Furthermore, we have attempted to incorporate the clincial and laboratory profiles of rheumatoid patients into the treatment scheme. Rheumatoid arthritis can be divided into three subgroups: seronegative rheumatoid arthritis , sero-positive rheumatoid arthritis, and hybrid rheumatoid arthritis. Such classification offers a guideline in selecting the most suitable anti-arthritic agents.
INTRODUCTION
To date, there are about fifteen NSAIDs available in the United States. More anti-rheumatoid agents of this type are waiting to get into the marketplace.
There might be a~ many as seven ty new drug applications to the United States Food and Drug Administration (FDA). With the relatively fast introduction of these fifteen NSAIDs, there appears to be some confusion as to their place in the treatment of rheumatoid disorders. This confusion may turn into a chaos if even a portion of the seventy newer NSAIDs are to be approved by the FDA. In this article, we will try to provide a relatively simple guideline which will aid clinicians in selecting suitable NSAJDs and also incorporating them into their treatment protocols with other anti-rheumatoid agents.
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Rheumatoid arthritis is a clinical diagnosis; and perhaps, it is even more appropriate to consider it as a clinical syndrome. Rheumatoid arthritis associated with viral disease, such as viral hepatitis, is a selflimited disease that poses no therapeutic challenge. However, rheumatoid arthritis as a manifestation of internal malignancies is, as a rule, notoriuosly resistant to even the most potent anti-rheumatoid treatment. These cases also exemplify the importance of making an accurate diagnosis and of the alertness of the attending physician during the course of treatment.
Among the laboratory findings, we pay special attention to the presence of rheumatoid factors (RF) and anti-nuclear antibodies (ANA). (Table I ). The term sero-negative rheumatoid arthritis refers to the negative test for RF, and sero-positive for the presence of circulating RF in rheumatoid arthritis patients. In cases of so-called hybrid rheumatoid arthritis, the immune profile is usually that of a positive test for RF and a positive ANA. (Table ll) . Drug therapy for rheumatoid arthritis can be guided by the aforementioned classification. Tables Ill, IV , and V give a summary of the treatment schedule which we follow for each type of rheumatoid arthritis.
SERO-NEGATIVE RHEUMATOID ARTHRITIS
As a rule, sero-negative rheumatoid arthritis cases appear to be clinically milder forms of rheumatoid arthritis and respond more readily to any drug t herapy. These clinically mild cases may be managed by administration of salicylates or one of the NSAIDs as a single agent. Clinically severe or therapy-resistant cases may be candidates for gold or penicillamine. However, it is important to stress the fact that the sero-negative state might actually be an early stage of sero-positive rheumatoid arthritis, since it usually takes about two to five years for rheumatoid factors to appear in the circulation after the first clinical signs of rheumatoid arthritis. Another group of sero-negative rheumatoid arthritis Steroids -Plaquenil Steroids -Plaquenil -Cytotoxic Steroids -Plaquenil -Anti-Inflammatory Agents Plaquenil -Anti-Inflammatory Agents patients is that group with positive anti-nuclear antibodies {ANA). The most common pattern for ANA staining is the so-called " ho mogenous" pattern which usually occurs at low titers, i.e., l :20 to 1 :80 by the peripheral blood FANA method.
(1) Some of these cases may remain sero-negative and ANA positive for years, although the ANA titer may decline with remissions. Some may progress, albeit rarely, into the hybrid rheumatoid arthritis state, i.e., positive RF, positive ANA. If the ANA pattern is that of "peripheral" staining, i.e., either the anti-DNP or anti-DNA antibody pattern, we follow these cases more closely since these patients may be progressing into hybrid rheumatoid arthritis or SLE.
Although it takes years for RF to appear in the blood, anti-nuclear antibodies seem to be present at the onset of rheumatoid diseases. From the treatment standpoint, we do not hesitate to treat those patients with positive anti-DNA or anti-DNP as hybrid rheumatoid arthritis, especially if there is any evidence of extra-articular involvement. The rheumatoid arthritis of SLE usually presents itself as a mild rheumatoid state. These subgroups of seronegative rheumatoid arthritis are summarized in Table Vl . SERO-POSITIVE RHEUMATOID ARTHRITIS Sero-positive rheumatoid arthritis cases make up the majority of cases since about 7511/o of rheumatoid arthritis patients exhibit a positive test for rheumatoid factors. However, about 250Jo to 40 07o of these cases may probably be classified as hybrid rheumatoid arthritis. The drug therapy for seropositive rheumatoid arthritis is summarized in Table  IV . The selection of these agents is made on the basis of clinical stage. Mild cases may respond to a single agent of either salicylates, NSAIDs, or phenylbutazone. If there is poor response to these agents, then the clinician would best consider any of the three so-called "remission-inducing agents:" gold, penicillamine, or anti-malarials. In our experience, most patients in this group would require more than one agent to produce a remission. These agent "combinations" are listed in Table IV . The most familiar combinations might be salicylatesgold, NSAIDs-gold, Plaquenil-gold, Plaquenil-gold-N SA ID s, or Plaquenil-gold-salicylates. Phenylbutazones (Butazolidin, Azolid) should be used for acute flare-ups confined to short-term duration because of bone marrow toxicity, although this complication appears to be extremely rare. It is, however, common to observe a significant sodium retention with the administration of the phenylbutazone group and therefore we almost always add a small dose of a diuretic to phenylbutazone therapy. Remission-inducing agents (gold, penicillarnine, anti-malarials) may take two to four months to exhibit significant clinical improvement. During this period, phenylbutazones or NSAIDs may be necessary to provide adequate comfort lo the patient. lf there is sufficient evidence for extra-articular involvement, with or without positive ANA, then the use of corticosteroids is indicated.
HYBRID RHEUMATOID ARTHRITIS
The extra-articular manjfestation may vary from a mild form of Sjogren's syndrome lo a severe systemic vasculitis. The most frequently involved organs are muscles, salivary and lacrimal glands, lungs, bone marrow, spleen and lymph nodes, peripheral nerves, serous membranes, heart, kidneys, intestines, and skin. Many terms and names, old and new, have been given to this group of rheumatoid conditions. We have tried to gather them in Table  VII . The titer of rheumatoid factors tends to be higher in this group. The titer and pattern of ANA may vary. The most common pattern is that of socalled " homogenous" staining with mild to moderate elevation in titers. In rare cases, one sees very high rheumatoid factor titers reaching into the millions, and anti-nuclear anti-body titers as high as 1:10,000 with a pattern of anti-DNA, anti-DNP, "speckled," anti-RNP, etc. The treatment of hybrid rheumatoid arthritis is outlined in Table V . The use of a single anti-arthritic agent is not s ufficient to induce a remission. Among the combinations which we have been using, a combined Plaquenil-steroid therapy seems preferable. There may be a synergistic effect in such a combination. In addition, anti-malarials have been known to have corticosteroid-sparing properties. We usually begin with 400 mg. of Plaquenil and 10-20 mg. of Prednisone or a Prednisone-equivalent daily. As soon as the patient shows adequate signs of remission, which may take four to eight weeks, the Prednisone dose is lowered by 500Jo. Plaquenil is continued at 400 mg. a day for four to eight months or longer; then it may be lowered to 200 mg. a day. Plaquenil appears to be safer with regard to eye complications if limited to a dosage of 200-400 mg. daily. In that dosage, it still acts as an effective antiinflammatory agent. The patients who are on this combination are required to have an ophthalmology exam at least once every six months. If this combination is used as a maintenance therapy, the lowest possible steroid dose of 2-5 mg. of Prednisone and 200 mg. of Plaquenil daily may be considered. The alternate-day steroid therapy is not effective in rheumatology. Except for the advanced-state osteoporosis, other side effects of steroids are usually reversible. Of course, skeletal complications are related to dosage and treatment duration. In cases of steroid complications or fear of complications, one may choose the combination of Plaquenil and one of the anti-inflammatory agents. In the presence of peptic ulcer disease, Plaquenil and gold may be the safer and better-tolerated combination.
Among the cytotoxic agents, lmuran is the only one approved by the FDA for rheumatoid arthritis treatment. In our experience, it is very rarely indicated. ff used, however, one of these agents may be added to the Plaquenil-Prednisone combination. Imuran appears to be the weakest immunosuppressive agent in the group. For effective immunosuppression, Cytotoxan is preferred. We have been using Cytotoxan along with the Plaquenil-Prednisone combination almost exclusively in cases of Wegener's Granulomatosis or systemic vasculitis. Methotrexate is reserved for severe psoriatic arthritis cases.
Plasmapheresis is another experimental treatment modality which may be restricted to certain acute severe cases of circulating immune complex conditions. Preferably, newer techniques which may try to filter out the harmful macromolecules should be sought out. (2) Page 116 -The Journal of IJ\M -Vol. 15 -0ctober 1983 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) The structural classification of these agents is given in Table Vlll. All of these agents possess peripheral analgesic activity, as well as antipyretic and antiinflammatory properties. They are also called prostaglandin inhibitors since they block the enzyme, cyclo-oxygenase, which converts arachidonic acid to prostaglandin. The anti-inflammatory effect can be observed within a few days after initiating the drug therapy.
The most common side effects peculiar to all of these agents are gastrointestinal in type: hyperacidity, gastritis, peptic ulceration, bleeding, diarrhea, etc. The central nervous system effects such as headaches, confusion, tinnitus and dizziness, may be more common with the indole group (lndocin, Clinoril, Tolectin, Zomax). The effects on the kidneys might include so dium retention, hyperkalemia, and allergic interstitial nephritis. Toxic hepatitis seems to be a very rare complication. In contrast to aspirin, Trilisate and Disalsid do not exhibit any significant anti-platelet or clotting factor effects.
Since the efficacy of these drugs is comparable, with the exception of the pyrazolomes, therapy selection by the treating physician is based on convenjence factors and patient tolerance. In the convenience or compliance factors, the drug half-life, i.e., the frequency of administration, is a factor. Drugs such as Motrin, Indocin, Nalfon, Tolectin, and Meclomen have half-lives of two to five hours thus requiring three or four times a day dosage regimens. Drugs with half-lives of fourteen to eighteen hours, such as Maprosyn, Clinoril, Butazolidin, and Azolid, require twice a day administration. Feldene, with the longest half-life of fifty hours, is a once a day agent.
If an analgesic is needed in addition io a NSAIDs, the use of acetaminophen (Tylenol) or a member of the codeine group is advised, rather than aspirin, Dolobid, Zomax, or Anaprox, because of the competitive action on cyclo-oxygenase caused by the latter group of drugs.
For more information on NSAIDs, the reader may wish to refer to one of the latest review articles. (3, 4) PENICILLAMINE (PCM) In the United States, penicillamine was approved for the treatment of "severe" rheumatoid arthritis in 1978. However, clinicians have been gaining experience in the use of PCM for about thirty years with the treatment of Wilson's disease, heavy metal poisoning, cystinuria, and Waldenstrom's macroglobulinemia. This long history has provided us with a valuable background on the drug in terms of its toxicities and the skills of its successful use. There is no lab test such as HLA-typing to identify a good responder to PCM therapy. The only way, chen, is to try this therapy once the indications for its use are met. Unfortunately, it might take two to four months to observe the true effectiveness of this drug provided that the patient's tolerance and the side effects are no problem. Penkillamine therapy is usually continued for several years. Most of the toxic reactions are observed during the first eighteen months of therapy. The responders exhibit a good clinical remission, as well as laboratory and roentgenographic improvement. Therefore, penicillamine has been cerrned a "disease-modifying agent." Its efficacy is similar to gold, with a 70-800/o remission rate. The failure of gold therapy is probably another indication for PCM therapy. Such failure does not seem to influence the chance of benefit from PCM. We have summarized the most helpful information on the administration and monitoring of PCM therapy in Table 1X .
Penicillin allergy is not a contraindication in the use of PCM. For minor side effects of PCM, such as nausea, vomiting, + 1 proteinuria, and mild skin rash, the treatment may be temporarily stopped or the dosage reduced. More serious side effects, such as a platelet count of less than 80,000/ mm3 , a leukocyte count of 3,000/mm3 or less, drug fever, persistent proteinuria of + 2 or greater, persi stent gastrointestinal toxicity, and autoimmune syndromes, may require the patient to permanently discontinue the use of PCM. (5) 
